AGORACOM News Flash

AGORACOM WIRE - FRIDAY MAY 25TH, 2012

FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc.

Aim to develop and manufacture the best technology graphite in the world
Additional shareholder value will come from investment in commercialized graphene through joint venture partner, Grafoid Inc.

Read More | *SPONSOR

INTERNATIONAL PBX VENTURES (TSX:PBX) Signs Copaquire Joint Venture Option Agreement - $90M Potential Payment Read More

AGORACOM Maintenance Alert: Friday Evening Downtime for About an Hour Read More

LOMIKO METALS (TSXV:LMR) Graphite and Zinc Price Outlook is Favourable Through 2013 Read More | *SPONSOR

Message: New Supply Agreement

Clavis

Rank: [?]

President

Points: [?]

23987

Rating: [?]

Votes: 222 Score: 3.5

Currently 3.6/5 Stars.

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

New Supply Agreement

posted on Jan 06, 09 08:45AM

January 6, 2009

PharmEng Announces New Supply Agreement With Multi-National Consumer Healthcare Company

TORONTO, ONTARIO--(Marketwire - Jan. 6, 2009) - PharmEng International Inc. (TSX VENTURE:PII), a full-service consulting and contract manufacturing company, today announced that Keata Pharma Inc. ("Keata"), its wholly owned subsidiary, has signed an agreement effective January 1, 2009 with a multi-national consumer healthcare company for the manufacturing of specific branded non-prescription drug products (the "Products") for Canada and various other international territories. This represents a new agreement for Keata, replacing an existing sub-contracting relationship with the multi-national consumer healthcare company with whom Keata had sales in excess of CDN $10 M in 2008.

Under the agreement, Keata will be the third party supplier to the multi-national consumer healthcare company for the Products for an initial two year term commencing from January 1, 2009 with an option to extend the agreement for two additional one-year terms.

"We are delighted to be continuing our relationship with this consumer healthcare company as the agreement underscores our dedication to quality and our commitment to continual cost improvement", stated Alan Kwong, CEO of PharmEng International Inc. "This supply agreement comes as a part of other multi-year contracts and will help to properly optimize our production capacity," concluded Mr. Kwong.

Keata manufacturing capabilities include pilot laboratories for formulation development, various capabilities of high shear mixing, container blending and equipment for modified release technology in an environment consistent with current Good Manufacturing Practices. Keata facilities have the necessary equipment and approvals to provide formulation development and testing services to manufacture and package products in solid and liquid dosage forms, including aseptic manufacturing. Keata's long-term goal is to develop capabilities in other dosage forms, such as suppositories, topicals and injectables.

About PharmEng International Inc.

PharmEng International Inc., headquartered in Toronto, Canada, is a full-service consulting and contract manufacturing company that serves the pharmaceutical and biotechnology industries in North America and internationally. Consulting services include project management, engineering, GMP, validation, calibration, regulatory compliance and certified training. Contract manufacturing includes pharmaceutical support, formulation development, laboratory testing, and finished solid dosage and liquid products. PharmEng's shares trade on the TSX Venture Exchange under the symbol PII. To find our more about PharmEng International Inc. (TSX-V: PII), visit our website at www.pharmeng.com.